Clinical Trials Browser

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Hematologic Neoplasms, Triple Negative Breast Neoplasms

NCT04913220 2026-02-04

A Study of SAR444245 Combined With Cemiplimab for the Treatment of Participants With Various Advanced Skin Cancers (Pegathor Skin 201)

Phase 1/2 Terminated

46 enrolled 22 charts

Dermatologic

Melanoma

NCT04157517 2026-01-29

A Study of Modakafusp Alfa (TAK-573) Given by Itself and Together With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors

Phase 1/2 Terminated

45 enrolled 44 charts

Dermatologic

Melanoma, Neoplasms

NCT02706353 2025-11-21

APX005M in Combination With Systemic Pembrolizumab in Patients With Metastatic Melanoma

Phase 1/2 Terminated

34 enrolled 18 charts

Dermatologic

Melanoma

NCT04725331 2025-11-21

A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors

Phase 1/2 Terminated

31 enrolled

BreastDermatologicSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasm Metastasis, Sarcoma, Vaccinia, Carcinoma, Merkel Cell, Triple Negative Breast Neoplasms

NCT03901573 2025-10-22

High-Risk Skin Cancers With Atezolizumab Plus NT-I7

Phase 1/2 Terminated

31 enrolled 12 charts

Dermatologic

Melanoma, Carcinoma, Merkel Cell

NCT05714553 2025-07-18

NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours

Phase 1/2 Terminated

19 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Squamous Cell Carcinoma of Head and Neck, Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Esophageal Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT03325101 2025-06-12

Dendritic Cell Therapy With Pembrolizumab for Metastatic or Unresectable Melanoma

Phase 1/2 Terminated

7 enrolled 11 charts

Dermatologic

Melanoma

NCT03997474 2025-03-07

ATL001 in Patients With Metastatic or Recurrent Melanoma

Phase 1/2 Terminated

13 enrolled 14 charts

Dermatologic

Melanoma

NCT05500508 2024-12-24

Oral AMXT 1501 Dicaprate in Combination With IV DFMO

Phase 1/2 Terminated

15 enrolled

BreastCNSDermatologicEndocrineGastrointestinalGynecologicHead & NeckOther solid neoplasmThoracic

Thyroid Cancer, Papillary, Diffuse Intrinsic Pontine Glioma, Mesothelioma, Malignant, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Glioma, Head and Neck Neoplasms, Melanoma, Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT01217411 2024-11-19

RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer

Phase 1/2 Terminated

5 enrolled 6 charts

BreastCNSDermatologicThoracic

Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma, Breast Neoplasms, Male, Small Cell Lung Carcinoma

NCT04198818 2024-07-19

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patient With Advanced Tumors

Phase 1/2 Terminated

37 enrolled 30 charts

DermatologicMyeloidThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Erdheim-Chester Disease

NCT04655157 2024-05-23

QUAD01

Phase 1/2 Terminated

2 enrolled 12 charts

Dermatologic

Melanoma

NCT00199342 2024-05-03

A Study of a Monoclonal Antibody, KW-2871, in Patients With Advanced Melanoma

Phase 1/2 Terminated

5 enrolled

Dermatologic

Melanoma

NCT05709821 2024-04-24

IMM60 and Pembrolizumab in Melanoma and NSCLC

Phase 1/2 Terminated

1 enrolled

DermatologicThoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Melanoma

NCT00003552 2024-03-04

Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Melanoma

Phase 1/2 Terminated

Dermatologic

Melanoma, Neoplasms, Skin Neoplasms

NCT04455503 2024-02-21

Study of Adjuvant Immunotherapy With EVX-02 and Anti-PD-1

Phase 1/2 Terminated

15 enrolled

Dermatologic

Melanoma

NCT02608268 2023-12-06

Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies

Phase 1/2 Terminated

252 enrolled 67 charts

DermatologicGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma

NCT02425306 2023-10-30

Mel63; CHAMP

Phase 1/2 Terminated

48 enrolled 13 charts

Dermatologic

Melanoma

NCT01559818 2023-06-22

A Long Term Follow up Study for Patients Who Previously Took Part in the Phase I Study IMM-101-001

Phase 1/2 Terminated

10 enrolled 12 charts

Dermatologic

Melanoma

NCT03637803 2023-06-01

Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors

Phase 1/2 Terminated

63 enrolled

DermatologicGenitourinaryThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Neoplasms

NCT04834973 2023-04-18

A Trial of Tigilanol Tiglate in Combination With Pembrolizumab in Stage IIIB to IV M1c-melanoma

Phase 1/2 Terminated

3 enrolled

Dermatologic

Melanoma

NCT00667953 2023-03-30

Study of Temzolomide and Gleevec in Advanced Melanoma

Phase 1/2 Terminated

32 enrolled 8 charts

Dermatologic

Melanoma

NCT04730349 2023-03-24

PIVOT IO 020

Phase 1/2 Terminated

15 enrolled 14 charts

CNSDermatologicLymphoidOther hematologic neoplasmSarcoma

Ependymoma, Glioma, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Medulloblastoma, Melanoma, Neoplasms, Neuroblastoma, Recurrence, Rhabdomyosarcoma, Sarcoma, Ewing, Leukemia, B-Cell

NCT03435640 2023-03-08

REVEAL

Phase 1/2 Terminated

64 enrolled 22 charts

BreastDermatologicGastrointestinalGenitourinaryHead & NeckSarcoma

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Renal Cell, Melanoma, Neoplasm Metastasis, Recurrence, Sarcoma, Colorectal Neoplasms, Carcinoma, Merkel Cell, Triple Negative Breast Neoplasms

NCT05219578 2022-12-09

RTX-224 Monotherapy in Patients With Solid Tumors

Phase 1/2 Terminated

7 enrolled

BreastDermatologicGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Melanoma, Triple Negative Breast Neoplasms

NCT00945269 2022-11-15

Therapeutic Autologous Lymphocytes, Aldesleukin, and Denileukin Diftitox in Treating Patients With Stage III-IV Melanoma

Phase 1/2 Terminated

3 enrolled

Dermatologic

Melanoma

NCT00145158 2022-10-10

Immunization With 8 Peptides Mixed With CpG 7909 or Montanide ISA51 in Patients With Metastatic Cutaneous Melanoma

Phase 1/2 Terminated

23 enrolled 8 charts

Dermatologic

Melanoma

NCT00145145 2022-10-07

Immunization With the MAGE-3.A1 Peptide Mixed With the Adjuvant CpG 7909 in Patients With Metastatic Melanoma

Phase 1/2 Terminated

1 enrolled 4 charts

Dermatologic

Melanoma

NCT03684785 2022-04-07

Intratumoral Cavrotolimod Combined With Pembrolizumab or Cemiplimab in Patients With Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, or Other Advanced Solid Tumors

Phase 1/2 Terminated

57 enrolled

Dermatologic

Melanoma, Skin Neoplasms, Carcinoma, Merkel Cell

NCT03347123 2022-02-28

A Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Participants With Advanced or Metastatic Malignancies (ECHO-208)

Phase 1/2 Terminated

11 enrolled 12 charts

DermatologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma

NCT02054104 2022-01-26

Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum

Phase 1/2 Terminated

21 enrolled 11 charts

DermatologicSarcoma

Melanoma, Sarcoma, Neoplasm, Residual

NCT00615160 2021-10-06

PTK/ZK in Disseminated Malignant Melanoma

Phase 1/2 Terminated

9 enrolled

Dermatologic

Melanoma

NCT02521870 2021-08-03

SYNERGY-001

Phase 1/2 Terminated

241 enrolled 23 charts

DermatologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Melanoma, Skin Neoplasms

NCT00961844 2021-02-26

Trial for Vaccine Therapy With Dendritic Cells in Patients With Metastatic Malignant Melanoma

Phase 1/2 Terminated

15 enrolled

Dermatologic

Melanoma

NCT03354962 2020-12-04

Induction of Immune-mediated aBscOpal Effect thrOugh STEreotactic Radiation Therapy in Metastatic Melanoma Patients Treated by PD-1 + CTLA-4 Inhibitors (BOOSTER MELANOMA)

Phase 1/2 Terminated

6 enrolled

Dermatologic

Diabetes Mellitus, Insulin-Dependent, 12, Melanoma

NCT02605083 2020-11-02

A Dose Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Advanced Solid Tumors

Phase 1/2 Terminated

66 enrolled

DermatologicHead & Neck

Melanoma, Neoplasms, Thyroid Diseases

NCT01590082 2020-09-02

Doxycycline, Temozolomide and Ipilimumab in Melanoma

Phase 1/2 Terminated

12 enrolled 6 charts

Dermatologic

Melanoma

NCT01308294 2020-06-11

LAG-3/IMP321

Phase 1/2 Terminated

16 enrolled 12 charts

Dermatologic

Melanoma

NCT03361228 2020-05-21

A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid Tumors

Phase 1/2 Terminated

5 enrolled 4 charts

DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Melanoma, Colorectal Neoplasms, Small Cell Lung Carcinoma

NCT03580382 2020-05-20

Study of CDX-3379, a Human Monoclonal Antibody Targeting ERBB3, in Combination With the MEK Inhibitor, Trametinib, in Patients With Advanced Stage NRAS Mutant and BRAF/NRAS Wildtype (WT) Melanoma

Phase 1/2 Terminated

3 enrolled 5 charts

Dermatologic

Melanoma

NCT01218867 2019-12-10

CAR T Cell Receptor Immunotherapy Targeting VEGFR2 for Patients With Metastatic Cancer

Phase 1/2 Terminated

24 enrolled 18 charts

DermatologicGenitourinary

Kidney Neoplasms, Melanoma, Neoplasm Metastasis

NCT03391050 2019-07-31

A Study of APR-246 in Combination With Dabrafenib in Resistant Patients With BRAF V600 Mutant Melanoma

Phase 1/2 Terminated

3 enrolled

Dermatologic

Melanoma, Neoplasm Metastasis, Skin Neoplasms

NCT02153905 2019-06-17

T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive

Phase 1/2 Terminated

3 enrolled 14 charts

BreastDermatologicGenitourinaryGynecologic

Urinary Bladder Neoplasms, Breast Neoplasms, Uterine Cervical Neoplasms, Kidney Neoplasms, Melanoma, Neoplasm Metastasis

NCT01723813 2019-03-12

Peptide Vaccinations Plus GM-CT-01 in Melanoma

Phase 1/2 Terminated

6 enrolled

Dermatologic

Melanoma

NCT00365937 2019-03-06

Immunization of Disease-Free Melanoma Patients With Different HLA-A2 Peptides

Phase 1/2 Terminated

19 enrolled

Dermatologic

Melanoma

NCT01350401 2019-01-10

Phase I/II Study to Assess the Safety and Activity of Enhanced TCR Transduced Autologous T Cells in Metastatic Melanoma

Phase 1/2 Terminated

4 enrolled 11 charts

Dermatologic

Melanoma, Neoplasm Metastasis

NCT00925132 2017-07-02

Treatment of Resistant Metastatic Melanoma Using Decitabine, Temozolomide and Panobinostat

Phase 1/2 Terminated

39 enrolled 8 charts

Dermatologic

Melanoma, Neoplasm Metastasis

NCT02413827 2017-04-07

A Study of Varlilumab (Anti-CD27) and Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or IV Melanoma

Phase 1/2 Terminated

9 enrolled

Dermatologic

Melanoma

NCT01026324 2017-04-04

Dinaciclib in Treating Patients With Stage III-IV Melanoma

Phase 1/2 Terminated

12 enrolled 9 charts

Dermatologic

Melanoma

Clinical Trials

Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases

A Study of SAR444245 Combined With Cemiplimab for the Treatment of Participants With Various Advanced Skin Cancers (Pegathor Skin 201)

A Study of Modakafusp Alfa (TAK-573) Given by Itself and Together With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors

APX005M in Combination With Systemic Pembrolizumab in Patients With Metastatic Melanoma

A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors

High-Risk Skin Cancers With Atezolizumab Plus NT-I7

NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours

Dendritic Cell Therapy With Pembrolizumab for Metastatic or Unresectable Melanoma

ATL001 in Patients With Metastatic or Recurrent Melanoma

Oral AMXT 1501 Dicaprate in Combination With IV DFMO

RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patient With Advanced Tumors

QUAD01

A Study of a Monoclonal Antibody, KW-2871, in Patients With Advanced Melanoma

IMM60 and Pembrolizumab in Melanoma and NSCLC

Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Melanoma

Study of Adjuvant Immunotherapy With EVX-02 and Anti-PD-1

Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies

Mel63; CHAMP

A Long Term Follow up Study for Patients Who Previously Took Part in the Phase I Study IMM-101-001

Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors

A Trial of Tigilanol Tiglate in Combination With Pembrolizumab in Stage IIIB to IV M1c-melanoma

Study of Temzolomide and Gleevec in Advanced Melanoma

PIVOT IO 020

REVEAL

RTX-224 Monotherapy in Patients With Solid Tumors

Therapeutic Autologous Lymphocytes, Aldesleukin, and Denileukin Diftitox in Treating Patients With Stage III-IV Melanoma

Immunization With 8 Peptides Mixed With CpG 7909 or Montanide ISA51 in Patients With Metastatic Cutaneous Melanoma

Immunization With the MAGE-3.A1 Peptide Mixed With the Adjuvant CpG 7909 in Patients With Metastatic Melanoma

Intratumoral Cavrotolimod Combined With Pembrolizumab or Cemiplimab in Patients With Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, or Other Advanced Solid Tumors

A Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Participants With Advanced or Metastatic Malignancies (ECHO-208)

Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum

PTK/ZK in Disseminated Malignant Melanoma

SYNERGY-001

Trial for Vaccine Therapy With Dendritic Cells in Patients With Metastatic Malignant Melanoma

Induction of Immune-mediated aBscOpal Effect thrOugh STEreotactic Radiation Therapy in Metastatic Melanoma Patients Treated by PD-1 + CTLA-4 Inhibitors (BOOSTER MELANOMA)

A Dose Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Advanced Solid Tumors

Doxycycline, Temozolomide and Ipilimumab in Melanoma

LAG-3/IMP321

A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid Tumors

Study of CDX-3379, a Human Monoclonal Antibody Targeting ERBB3, in Combination With the MEK Inhibitor, Trametinib, in Patients With Advanced Stage NRAS Mutant and BRAF/NRAS Wildtype (WT) Melanoma

CAR T Cell Receptor Immunotherapy Targeting VEGFR2 for Patients With Metastatic Cancer

A Study of APR-246 in Combination With Dabrafenib in Resistant Patients With BRAF V600 Mutant Melanoma

T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive

Peptide Vaccinations Plus GM-CT-01 in Melanoma

Immunization of Disease-Free Melanoma Patients With Different HLA-A2 Peptides

Phase I/II Study to Assess the Safety and Activity of Enhanced TCR Transduced Autologous T Cells in Metastatic Melanoma

Treatment of Resistant Metastatic Melanoma Using Decitabine, Temozolomide and Panobinostat

A Study of Varlilumab (Anti-CD27) and Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or IV Melanoma

Dinaciclib in Treating Patients With Stage III-IV Melanoma